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Since the identification of BRCA1 (Miki et al, 1994) and BRCA2
(Wooster et al, 1995), presymptomatic DNA screening for
disease-related BRCA1 and BRCA2 mutations has become
possible. Now that more breast cancer patients seem to be aware
of the existence of these tests, a greater demand for testing on
germline BRCA1/2 mutations can be expected. Despite clinical
benefits, testing all breast cancer patients for genetic predisposi-
tion is, however, still controversial. It is hampered by, among
other things, an incomplete knowledge about the frequency of
disease-related mutations among patients not selected on the basis
of family history status.
In two populations of young breast cancer patients not selected
on family history, prevalences of disease-related BRCA1 mutations
of 7.5% and 3.8% respectively have been observed (Langston et al,
1996; Southey et al, 1999). In another breast cancer population, not
selected for age at diagnosis or family history, the frequency of
disease-related BRCA1 mutations was 3.3% (Newman et al, 1998).
However, the prevalence of BRCA1/2 mutations may differ
between populations, while certain mutations may predominantly
be found in populations with a specific ethnic background. The
frequencies of such founder mutations, like the 185delAG and the
5382insC in BRCA1 observed among Ashkenazi Jews, may be
much higher when compared to non-founder mutations. Among
unselected Ashkenazi breast cancer patients the observed preva-
lence of the two founder mutations together is 3.7–8.9%
(Abeliovich et al, 1997; Fodor et al, 1998; Hartge et al, 1999).
Several mutations in BRCA1 have been identified as major
founders in the Netherlands (Peelen et al, 1997; Petrij-Bosch et al,
1997). To gauge the contribution of BRCA1 mutations to the inci-
dence of breast cancer in the general population, a hospital-based
study was undertaken. Breast cancer patients diagnosed between
1984 and 1996 at the Leiden University Medical Center (LUMC)
were tested for the presence of germline BRCA1 mutations.
Several characteristics (age at diagnosis of the first breast cancer,
family history of cancer and bilateral breast cancer) were
collected, to assess their relation to BRCA1 mutation status in this
particular patient population.
MATERIALS AND METHODS
Population
From January 1984 to November 1996 all primary invasive
breast cancer patients who were surgically treated at the Leiden
Academic Hospital (LUMC), regardless of age or family history,
were asked to provide a blood sample for research purposes.
The total number of patients treated at the LUMC for invasive
breast carcinoma in this period was 1099. This has led to 642
(58%) patients from whom lymphocyte DNA was available.
Two of these patients were male. A total of 457 patients,
including six males, did not provide a blood sample because
they were not asked, or declined, to participate. There was no
statistically significant difference between the patients who did
or who did not provide a blood sample with respect to mean age
at diagnosis of their first breast cancer (57.5 years-of-age,
95%CI: 56.4–58.6 and 58.2 years-of-age, 95%CI 56.8–59.5,
respectively). The range of ages at diagnosis was 27–91 years-
of-age and 23–96 years-of-age, respectively, with a median of
58 years for both groups.
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doi: 10.1054/ bjoc.2000.1331, available online at http://www.idealibrary.com on Data were obtained regarding the family history of cancer of
first- and second-degree relatives. The following was assessed:
number of relatives, number of relatives, alive and dead, number
of relatives with cancer, all related to type of relationship to index.
For the affected relatives the following was assessed: type of rela-
tionship with index, type of cancer and bilaterality, if there was
any breast cancer. We did not confirm information by pathology or
other evidence. As the medical record provided limited informa-
tion on family history, the general practitioners of the patients
alive on 1 June 1997 (n = 427) were contacted. This resulted in the
approval to send a questionnaire to 318 patients. Completed ques-
tionnaires were received from 269 patients (overall response rate
of 63%). For the patients who had died before 1 June 1997 (n =
215), information was collected from the medical records and
additional information was retrieved from the general practitioner
of the patients. For the patients who did not fill in the question-
naire but were alive on 1 June 1997 (n = 158), the only source of
information was the medical record.
Data on the prevalence of bilateral breast cancer (synchronic
and metachronic) among the 642 tested patients, were collected
from the tumour registry of the LUMC, assessed August 1997.
The 642 patients of whom lymphocyte DNA was available were
tested anonymously for mutations in BRCA1. The Committee of
Medical Ethics of the LUMC approved the study.
The Dutch BRCA1 mutation spectrum
A national survey in January 1999 among eight clinical genetic
centres in the Netherlands resulted in a total of 370 independently
identified breast cancer families with a known mutation in
BRCA1. In general, counsellees are offered a DNA test when they
have an a priory chance >10% of being a BRCA1 carrier (Couch
et al, 1997; Peelen et al, 1997; Shattuck-Eidens et al, 1997). The
DNA test consists of the PTT for exon 11 (Hogervorst et al, 1995),
supplemented with fragment-analysis (by SSCP or DGGE) of the
smaller exons (usually exons 2, 5, 16, 20), and specific PCRs for
the junction fragments of the large genomic founder deletions
among the Dutch (Petrij-Bosch et al, 1997). The resulting muta-
tion spectrum presently consists of 69 different mutations, 10 of
which comprise 68% of the total set. There are 295 frame-shifting,
49 nonsense, 29 splice-site and four unclassified variants in this
set, but no missense mutations.
DNA-isolation and genomic PCR
Genomic DNA was extracted from peripheral white blood cells
with a salting-out method (Millar et al, 1998). All PCR reactions
were carried out in 15 µ l volume in multiwell plates, containing
approximately 100 ng µ l–1 genomic DNA, 5–10 pmol of each
primerset, 0.75 U AmpliTaq polymerase (Perkin Elmer/Cetus) and
1.5 µ l × 10 RM buffer (500 mM KCl, 100 mM TRIS-HCl pH 8.4,
25 mM MgCl2, 2 mg ml–1 BSA, 2 mM dNTPs). After heating at
94° C for 5 min, the PCR consisted of 30 cycles (45 s at 94° C, 1
min at 58° C and 1.5 min at 72° C), followed by an additional step
of 5 min at 72° C.
Detection of small deletions and insertions (DSDI)
Twenty primer pairs were designed in the BRCA1 regions in such
a way that the following mutations could be detected: 1129delA,
1135insA, 1191delC, 1240delC, 1406insA, 1411insT, 1438delT,
185delAG, 185insA, 2138delA, 2312del5, 2329delC, 2331del4,
2804delAA, 2809insA, 2845insA, 2846del4, 2883del4,
3109insAA, 3600del11, 3604delA, 3875del4, 3889delAG,
3938insG, 4010delTTC, 4184del4, 4284delAG, 4370delGT,
5256delG, 5382insC, 5389del7, 5448insC, del ex 13–16,
IVS12–1643del3835, IVS21–36del510. Using the information
available on the Dutch Mutation Database (see section Electronic
database information) it can be estimated that aproximately 75%
of all currently known Dutch and Belgian mutations, including the
large genomic deletions (Peelen et al, 1997; Petrij-Bosch et al,
1997) are traced with DSDI. All forward primers were labeled
with a Hex, Tet or 6Fam fluorescent label. To facilitate multi-
plexing a 20mer M13 tail (5′ -GCG GTC CCA AAA GGG TCA
GT) was attached to forward and reversed primers (Shuber et al,
1995). Three multiplex PCR reactions were developed to amplify
all fragments (available upon request). Subsequently PCR samples
from the three different reactions were pooled in a 1:1:3 ratio for
Tet, 6Fam and Hex respectively. 1 µ l was taken and 0.5 µ l
TAMRA-500, 0.5 µ l Dextran-Blue and 3.5 µ l formaline were
added. After 3 min denaturation at 94° C 1 µ l of the sample
mixture was loaded into a 6% Longranger™ gel on an AB1377-
XL™ automated sequencer. Electrophoresis was performed for 
7 h at 1680 V, 51° C at filterset C. Gel analysis was performed with
GeneScan Analysis® 3.1 software. In the parameter files the
Smooth Options and the Slit Peak Correction were set to None.
For the Size Calling Method the second-order-least-squares option
was used. After gel analysis, sample data were transferred to
Genotyper™ 2.0 program. Software was programmed to call for
suspected mutations if two peaks were present in a selected
window. Possible variants were reamplified as simplex PCR prod-
ucts. After confirmation, the potential variants were directly
sequenced from both strands on an AB1377 automatic sequencer
using the BigDye Terminator (Applied Biosystems of Perkin
Elmer) chemistry and the same primers for amplification of the
fragments.
Statistical methods
Assuming that DSDI will detect ~75% of Dutch and Belgian
mutations, the mutation frequency in the general population in the
Netherlands was considered to be 1/0.75 times the detected
frequency. For the proportion of cases that carry a germline
BRCA1 mutation the 95% confidence interval was calculated
using the exact method described by Martin and Altman (1989)
(exact method available upon request). For the estimated propor-
tion that carry a germline mutation in the general population, the
upper and lower limit of the 95% confidence interval were consid-
ered to be 1/0.75 times the limits given by the confidence interval
of the observed proportion.
RESULTS
Ten out of 642 genotyped breast cancer patients (1.6%) (Figure 1)
contained a protein-truncating BRCA1 mutation (Table 1). One of
these mutations, 2845insA in exon 11, had never been reported
before. The 510bp deletion of exon 22 (del510) was observed four
times in this series, whereas the other observed Dutch founder
mutations, the 3835bp deletion of exon 13 (del3835), 1411insT
and 2804delAA, were each detected once. The two remaining
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founder 5382insC. Furthermore, one inframe deletion was
detected, of which relation with disease-risk is unknown. All
mutation carriers were females with a mean age at diagnosis of the
first breast cancer of 40.3 years (95%CI 36.2–44.4) and a range of
30–48 years-of-age. Stratified by age group the highest prevalence
(7.8%) was observed between 30 and 39 years-of-age at diagnosis
(see Table 2). All other mutation carriers were observed among
breast cancer patients of 40–49 years at diagnosis. In this age-
group the prevalence of BRCA1 mutations was 3.9%. Adjusted for
the 75% sensitivity of DSDI the prevalence under 40 years-of-age
and under 50 years-of-age was estimated to be 9.5% and 6.4%,
respectively. The prevalence of disease related BRCA1 mutations
in the general population not selected for age at diagnosis was esti-
mated to be 2.1% (see Table 2).
Complete data on the family history of cancer were available
from the six mutation carriers (MC1–6) who filled in the question-
naire (Table 3). From the other four mutation carriers two (MC7,
MC8) had died, and two (MC9 and MC10) did not return the ques-
tionnaire. From the patients who did not fill in the questionnaire
the information regarding family history of cancer was mostly
limited to breast cancer and only if the relative developed breast
BRCA1 prevalence in breast cancer patients 721
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Figure 1 DSDI pattern of a healthy control (A), of patient MC9 (B) and of patient MC7 (C)
Table 1 Characteristics of mutation carriers and types of the observed BRCA1 mutations
Identification Age at Bilateral Mutation Exon Type Change No. of
code diagnosis breast citations in
(years) cancer BICa/DMDb
(age at
diagnosis)
disease-related
MC1 33 no del510 22 Frameshift stop 1805 35/57
MC2 45 no del510 22 Frameshift stop 1805 35/57
MC3 46 no del510 22 Frameshift stop 1805 35/57
MC4 48 no del510 22 Frameshift stop 1805 35/57
MC5 30 yes(43) 3875del4 11 Frameshift stop 1262 22/3
MC6 34 no 5382insC 20 Frameshift stop 1829 136/17
MC7 35 no del3835 13 Frameshift stop 1398 22/30
MC8 42 no 1411insT 11 Frameshift stop 434 13/21
MC9 45 no 2804delAA 11 Frameshift stop 901 42/45
MC10 45 no 2845insA 11 Frameshift stop 916 0/0
relation with disease unknown
MC11 39 no 4010delTTC 11 In-frame deletion 0/0
deletion serine
1297
a Breast Cancer Information Core (assessed January 1999); b Dutch and Belgian Mutation Database (n = 370)cancer before our proband was diagnosed. Five out of 10 mutation
carriers had a first-or second-degree relative with breast cancer.
Even when the mutation carriers who did not fill in the question-
naire are excluded, the proportion of mutation carriers without a
first-degree relative with breast or ovarian cancer is three out of
six. The proportion of first-degree or second-degree relatives with
breast and/or ovarian cancer, however, is one out of six. Bilateral
breast cancer was recorded in 61 out of 631 mutation-negative
patients (9.7%, 95%CI 7.5–12.2%) and in one out of 10 mutation-
positive patients (10%, 95%CI 2.5–44.5%).
DISCUSSION
A hospital-based population of 642 breast cancer patients, unse-
lected for family history or age at diagnosis, was screened for
disease-related BRCA1 mutations. This study population appears to
be a good representation of the general breast cancer population in
the Netherlands. Although a slight bias towards younger age cases
was seen in our series compared to the Dutch breast cancer popula-
tion in general (Coebergh et al, 1995), the difference was so subtle
that it cannot plausibly have made a dramatic impact on our preva-
lence estimates. The likelihood of selecting patients with a positive
family history of breast or ovarian cancer is probably small, since
most of the patients were included before 1995, i.e. before public
awareness on hereditary cancer increased due to the identification of
BRCA1. Furthermore, we think that medical awareness on heredi-
tary cancer was also limited since we did not find much information
regarding family history in the medical record.
Ten disease-related BRCA1 mutations were detected in this
study population (1.6%), which is probably an underestimate
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Table 2 Frequency of disease-related BRCA1 mutations by age-group
Age- Number Proportion Number Proportion Adjusted Proportion
group tested of total (%) positive positive (% cumulative predicted
(95% CI)) proportion (%)b
positive (%a
(95%CI))
<30 5 0.8 0 0 (0–52) 0 (0–69) 7.5
30–39 51 7.9 4 7.8 (2.2–18.9) 9.5 (2.7–23.1) 5.1
40–49 154 24.0 6 3.9 (1.5–8.2) 6.4 (3.1–11.5) 2.2
50–59 158 24.6 0 0 (0–2.3) 3.6 (1.7–6.6) 1.4
60–69 128 19.9 0 0 (0–2.8) 2.7 (1.3–4.9) 0.8
70+ 146 22.7 0 0 (0–2.5) 2.1 (1.1–3.9) –
total 642 100 10 1.6 (0.8–2.9) 2.1 (1.1–3.9) 1.70
a Assuming that DSDI will have missed 25% of the mutations; b Proportion predicted by Ford et al (1995)
Table 3 Family history of cancer in the disease-related BRCA1 mutation carriers
Identification Number of Number of Total Total Type of malignancy and
code first-degree second-degree number of Number of relativeb with this type of
relatives relatives with first/ relatives with malignancy
with breast breast (br) or second- malignancies
(br) or ovarian (ov) degree other
ovarian (ov) cancerc female than breast
cancerb relatives or ovarian
cancer
MC1 0 2 ov (p) 2/5 4 lymphoma (Pu), throat or
lung cancer (Pu),
gastric cancer (Gf),
leukaemia (Gf)
MC2 1 br (S) 1 br (p) 4/6 7 cancer of intestine (B, Pu),
lung carcinoma (F),
leukaemia (2 Ma),
Esophageal carcinoma (Pu)
MC3 0 2 br (p, m) 2/11 2 lung carcinoma (2 Pu)
MC4 0 0 1/6 9 throat carcinoma (M),
lung cancer (F, 3 Mu),
cancer of intestine (Mu, Gmm),
liver cancer (Pu, Gmp)
MC5 1 br (S), 1 ov (M) 3 br (2m, p) 2/7 1 melanoma (Gfp)
MC6 1 br (S) 0 4/3 2 leukaemia (S), uterine
cancer (M)
MC7a 0 0 br, ? ov unknown 1 known thyroid carcinoma (F)
MC8a 0 0 br, ? ov unknown 1 known melanoma (B)
MC9a 0 br, ? ov 0 br, ? ov unknown unknown
MC10a 0 br, ? ov 0 br, ? ov unknown unknown
a Patient did not fill in the questionnaire; b F = Father, M = Mother, S = Sister, B = Brother, Pu/Pa = paternal uncle/aunt, Mu/Ma = maternal uncle/aunt, Gmp/Gfp
= paternal grandmother/father, Gmm/Gfm = maternal grandmother/father; cp = paternal, m = maternal; ? ov = history of ovarian cancer is not knownconsidering that our screening-assay is not 100% sensitive. This
prevalence is in accordance with previous estimations by the
Breast Cancer Linkage Consortium (BCLC) (Ford et al, 1995)
(Table 1), but slightly lower than the three carriers found among
120 white breast cancer patients from a US North Carolina popula-
tion (Newman et al, 1998). Thus, despite strong founder-effects of
several BRCA1 mutations among the Dutch (Peelen et al, 1997),
the overall population frequency of BRCA1 does not seem to be
higher than predicted by the BCLC. This is in sharp contrast with
the Ashkenazi Jewish population, where two BRCA1 founder-
mutations occur at a frequency eight times that of other popula-
tions. Our observed prevalence does not substantially differ from
predictions by the BCLC, which suggests that the overall BRCA1
penetrance will also come out as estimated by the BCLC, i.e. about
50% before age 50 (Easton et al, 1995). However, an extrapolation
to the general breast cancer population in the Netherlands should
be performed with caution, firstly because it assumes that our
assay will detect 75% of all mutations prevalent among the Dutch.
Even though over 1500 families have been screened in eight
Cancer Family Clinics, this screening does not entail the entire
BRCA1 coding region and therefore the currently known ‘Dutch
mutation spectrum’ might still be incomplete. In addition, this
spectrum could be different from the one present among the
general breast cancer population. Secondly, our study population is
clinic-based and may therefore differ from the general breast
cancer population in the Netherlands, even though this is not
supported by our clinical data.
All BRCA1 mutation carriers, or 10 out of 210 (5%), were
under 50 years-of-age at diagnosis of their first breast cancer. We
found no carrier that had been diagnosed under 30 years-of-age.
Previous population-based studies also found small proportions of
mutation carriers among patients under 30 (Langston et al, 1996;
Newman et al, 1998; Southey et al, 1999), with one exception
reporting 11.4% (Malone et al, 1998). Based on linkage data from
high-risk families, the BCLC estimated that 7.5% of the patients in
this age-group would be carrying a BRCA1 mutation (Table 1).
Families with multiple cases of breast cancer in different genera-
tions were needed for this type of analysis and selection for
extremely young ages at diagnosis could have occurred.
Nonetheless, the small number of patients under 30 in our series (n
= 5), and in other studies (Langston et al, 1996; Newman et al,
1998; Southey et al, 1999), results in wide confidence intervals.
Further research will therefore be required to establish the preva-
lence of BRCA1 in this particular group of patients.
An increased risk of having a BRCA1 or BRCA2 mutation was
observed among Dutch families with a small number of female
relatives if there is a relative with bilateral breast cancer present
(Ligtenberg et al, 1999). The results of our study, however, suggest
that bilateral breast cancer (as an isolated parameter) in the patient
herself is not indicative for BRCA1 mutation status, since the
proportion of patients with bilateral breast cancer in our study was
the same in carriers and non-carriers.
The number of carrier patients in our study without a first-
degree relative with breast or ovarian cancer is striking. This is
probably due to a stochastic deficit of first-degree females at risk
(Table 3). When both first- and second-degree female relatives are
included, the proportion of carrier patients with a positive family
history is much higher. The observation that a number of mutation
carriers do not have a relative with breast or ovarian cancer is
nevertheless in accordance with previous studies by others
(FitzGerald et al, 1996; Tonin et al, 1996; Abeliovich et al, 1997;
Hartge et al, 1999). It could mean that some mutations confer a
lower penetrance than previously estimated, as has been reported
for the 185delAG and the 5382insC mutations in the Ashkenazi
Jewish population (Struewing et al, 1997; Fodor et al, 1998). A
candidate for such a reduced penetrance mutation in the
Netherlands is the del510, since this mutation was observed four
times in our series, whereas 1.5 were expected on the basis of its
prevalence in high-risk families (Table 1). In contrast, the Dutch
founder-mutations del3835, 1411insT and 2804delAA were identi-
fied in the proportions anticipated on this basis. As the number of
affected relatives among the four carriers of the del510 mutation
shows a wide variation, it seems likely that this mutation causes
heterogeneous cancer risks in different families through genetic
and environmental modifying effects (Devilee, 1999).
In conclusion, our results indicate that about 5% of the Dutch
breast cancer patients diagnosed under the age of 50 can be attrib-
uted to BRCA1. Furthermore, a substantial proportion of mutation
carriers did not have a first-degree relative with breast cancer. This
suggests that the overall BRCA1 penetrance in the Dutch popula-
tion will likely come out in the same order of magnitude as esti-
mated previously by the BCLC, although some evidence for risk
heterogeneity was also obtained. Further investigation is needed to
establish the full mutation spectrum and associated cancer risks in
each category of patients.
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